What's Going On With Kazia Therapeutics Shares Thursday?
What's Going On With Kazia Therapeutics Shares Thursday?
Kazia Therapeutics (NASDAQ:KZIA) stock is trading higher on Thursday on possible continued momentum from the company's Wednesday press release.
kazia therapeutics (纳斯达克:KZIA)股票周四交易较高，可能受周三公司新闻发布会的持续推动。
The Details: The company announced results from its Phase II/III trial in regards to the treatment of glioblastoma, a type of brain cancer.
详情：该公司发布了其II/III期试验有关治疗胶质母细胞瘤（一种脑癌）的结果。
The trial, containing 313 participants, compared the effectiveness of paxalisib versus the current standard of care. The results showed a 3.8 month increase in overall survival, or about a 33% improvement. The median overall survival was 14.77 months for paxalisib-treated patients compared to 13.84 months for patients treated with standard care.
试验共有313名参与者，比较了帕可司坦与目前的标准治疗的有效性。结果显示总生存期增长了3.8个月，即改善了约33%。帕可司坦治疗的患者的中位总生存期为14.77个月，而标准治疗的患者为13.84个月。
In a preplanned additional analysis, the median overall survival was 15.54 months for those treated with paxalisib compared to 11.89 months for those receiving standard care. A sensitivity analysis also showed similar results: 15.54 months for paxalisib-treated patients and 11.70 months for those on standard care.
在一次预先安排的额外分析中，接受帕可司坦治疗的患者的中位总生存期为15.54个月，而接受标准治疗的患者为11.89个月。敏感性分析也显示了类似的结果：接受帕可司坦治疗的患者中位总生存期为15.54个月，接受标准治疗的患者为11.70个月。
These findings match the results from an earlier phase II study by the company.
这些发现与该公司早期II期研究的结果相符。
"Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult to treat glioblastoma population. We look forward to discussing possible approaches for an accelerated approval pathway for paxalisib with the FDA," said Kazia CEO John Friend.
“在两个独立研究中拥有可比的总生存数据是在难治性胶质母细胞瘤人群中取得的一个引人注目的结果。我们期待与FDA讨论帕可司坦的加速批准途径可能的途径，” Kazia首席执行官约翰·弗伦德表示。
KZIA Price Action: At the time of publication, Kazia Therapeutics shares are trading 58.5% higher at $1.06 per data from Benzinga Pro.
Kazia Therapeutics股票价格走势：根据Benzinga Pro的数据，截止本文发表时，Kazia Therapeutics股价上涨了58.5%，为每股1.06美元。
- UniQure Soars on New Huntington's Disease Study Data
- UniQure对亨廷顿病新研究数据的飙升
Image: Akava Photo from Pixabay
图片来自Pixabay的Akava照片。